OncLive® On Air
In OncLive® On Air, you can expect to hear interviews with academic oncologists on the thought-provoking oncology presentations they give at the OncLive® State of the Science Summits. The topics in oncology vary, from systemic therapies, surgery, radiation therapy, to emerging therapeutic approaches in a particular type of cancer. This includes lung cancer, breast cancer, gastrointestinal cancers, hematologic malignancies, gynecologic cancers, genitourinary cancers, and more.
Pancreatic Cancer Experts Map Treatment Sequencing With Liposomal Irinotecan and Beyond
In today’s episode, we spoke with Raji Shameem, MD, and Shubham Pant, MD, MBBS. Dr Shameem is a clinical assistant professor of medicine at the Orlando College of Osteopathic Medicine, an assistant professor of Medicine at the University of Central Florida, and a physician at Orlando Health. Dr Pant is a professor in the Department of Gastrointestinal Medical Oncology and the Department of Investigational Cancer Therapeutics, as well as the director of Clinical Research at The Sheikh Zayed Center For Pancreatic Cancer Research at The University of Texas MD Anderson Cancer Center in Houston.
In our ex...
Integrating Precision Pathways in HER2+ Gastroesophageal Adenocarcinoma—Testing, Treatment, and Supportive Care
Highlights from the PER® CME activity "SimulatED: Integrating Precision Pathways in HER2+ Gastroesophageal Adenocarcinoma — Testing, Treatment, and Supportive Care" — this podcast is not certified for credit. To participate in the full accredited activity and earn CME credit, use the link below.
In this podcast, experts Geoffrey Y. Ku, MD, and Sunnie Kim, MD, discuss essential biomarker testing for advanced gastroesophageal adenocarcinoma, first-line treatment selection for HER2-positive metastatic disease in light of data from HERIZON-GEA-01 (NCT05152147), management of treatment-related diarrhea and other adverse events, and HER2 retesting at disease progression.
Earn CME credit by completing the f...
Fast-Moving Treatment Advances Shape B-Cell Lymphoma Care
In this episode of Oncology Unplugged, host Chandler Park, MD, a medical oncologist at Norton Cancer Institute in Louisville, Kentucky, was joined by Joshua Brody, MD, the director of the Lymphoma Immunotherapy Program at the Mount Sinai Tisch Cancer Center and a faculty member of the Icahn Genomics Institute in New York, New York.
Their discussion centered on the rapidly evolving treatment landscape for B-cell non-Hodgkin lymphomas, highlighting a wave of recent advances across frontline and relapsed diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) management. Drs Park and Brody framed this current era as...
Metastatic Non-Small Cell Lung Cancer 2026 UPDATE
Two Onc Docs, hosted by Samantha A. Armstrong, MD, and Karine Tawagi, MD, is a podcast dedicated to providing current and future oncologists and hematologists with the knowledge they need to ace their boards and deliver quality patient care. Dr Armstrong is a hematologist/oncologist and assistant professor of clinical medicine at Indiana University Health in Indianapolis. Dr Tawagi is a hematologist/oncologist and assistant professor of clinical medicine at the University of Illinois in Chicago.
In this episode, OncLive On Air® partnered with Two Onc Docs to deliver a comprehensive, board-focused review of metastatic non–small cel...
Precision Immunotherapy, PET-Adapted Regimens, and Novel Targets Are Redefining Hodgkin Lymphoma Care: With Chandler Park, MD; Joshua Brody, MD
In this episode of Oncology Unplugged, host Chandler Park, MD, a medical oncologist at Norton Cancer Institute in Louisville, Kentucky, was joined by Joshua Brody, MD, the director of the Lymphoma Immunotherapy Program at the Mount Sinai Tisch Cancer Center and a faculty member of the Icahn Genomics Institute in New York, New York.
Their discussion centered on the evolving frontline and relapsed treatment landscape in Hodgkin lymphoma, highlighting the field’s decades-long shift away from intensive chemotherapy and radiation toward better-tolerated, biologically targeted regimens. Drs Park and Brody framed Hodgkin lymphoma as a rare success story in...
The ADC Revolution in Metastatic Breast Cancer: Redefining Treatment Selection and Sequencing
Highlights from the PER® CME activity "The ADC Revolution in Metastatic Breast Cancer: Redefining Treatment Selection and Sequencing" — this podcast is not certified for credit. To participate in the full accredited activity and earn CME credit, use the link below.
In this podcast, experts Seth A. Wander, MD, PhD, Reshma L. Mahtani, DO, and Shanu Modi, MD, review pivotal data regarding the use of antibody-drug conjugates in the treatment of metastatic triple-negative breast cancer, and discuss how they apply these data in the management of their patients.
Earn CME credit by completing the full accredited act...
Current Approaches and Future Directions for Early-Stage TNBC
Highlights from the PER® CME activity "Current Approaches and Future Directions for Early-Stage TNBC" — this podcast is not certified for credit. To participate in the full accredited activity and earn CME credit, use the link below.
In this podcast, experts Nour Abuhadra, MD, and Antonio Giordano, MD, PhD, discuss the emerging role of antibody-drug conjugates (ADCs) in early-stage triple-negative breast cancer (TNBC) and the practice implications of ongoing post-neoadjuvant trials.
Earn CME credit by completing the full accredited activity (available through July 31, 2027): https://www.gotoper.com/courses/current-approaches-and-future-directions-for-early-stage-tnbc
This podcast, including the narration, was dev...
Non–Small Cell Lung Cancer 2026 UPDATE
Two Onc Docs, hosted by Samantha A. Armstrong, MD, and Karine Tawagi, MD, is a podcast dedicated to providing current and future oncologists and hematologists with the knowledge they need to ace their boards and deliver quality patient care. Dr Armstrong is a hematologist/oncologist and assistant professor of clinical medicine at Indiana University Health in Indianapolis. Dr Tawagi is a hematologist/oncologist and assistant professor of clinical medicine at the University of Illinois in Chicago.
In this episode, OncLive On Air® partnered with Two Onc Docs to deliver a comprehensive, board-focused review of early-stage and locally a...
FDA Approval Insights: Integrating RP1 Plus Nivolumab Into Post–PD-1 Melanoma Practice: With Michael K. Wong, MD, PhD, FRPC
In today's episode, we spoke with Michael K. Wong, MD, PhD, FRPC. Dr Wong is a physician at Roswell Park Comprehensive Cancer Center in Buffalo, New York.
In our exclusive interview, Dr Wong discussed the significance of the FDA’s accelerated approval of vusolimogene oderparepvec-wtpg (Tudriqev; RP1) in combination with nivolumab (Opdivo) for adult patients with unresectable advanced cutaneous melanoma whose disease progressed on a prior PD-1–blocking antibody–based regimen. He noted that this approval followed a lengthy regulatory trajectory, including two prior complete response letters, before a third biologics license application was accepted in June 2026 and a...
Immunotherapy Decision-Making in CSCC Sits at the Intersection of Efficacy and Comorbidity: With Eric D. Whitman, MD; and Francis Paul Worden, MD
Eric D. Whitman, MD, and Francis Paul Worden, MD, discuss the integration of immunotherapy into the cutaneous squamous cell carcinoma (CSCC) treatment paradigm and key considerations for navigating treatment selection for this patient population. The pair also highlight strategies to maximize efficacy and minimize toxicity with immunotherapy-based approaches.
FDA Approval Insights: Iberdomide-Based Therapy Adds Another Option for R/R Myeloma: With Sagar Lonial, MD, FACP, FASCO
In today’s episode, we welcomed Sagar Lonial, MD, FACP, FASCO, to discuss the significance of the August 2026 FDA accelerated approval of iberdomide (Zenbexus) plus daratumumab and hyaluronidase-fihj (Darzalex Faspro) and dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least 1 prior line of therapy including a proteasome inhibitor and an immunomodulatory agent. Dr Lonial is a professor and chair of the Department of Hematology and Medical Oncology at Emory University School of Medicine, as well as chief medical officer at Winship Cancer Institute of Emory University in Atlanta, Georgia.
I...
𝘔𝘌𝘛 Alterations in NSCLC: Applying Diagnostic Advances and Targeted Therapies in a New Era of Treatment
Highlights from the PER® CME activity "MET Alterations in NSCLC: Applying Diagnostic Advances and Targeted Therapies in a New Era of Treatment" — this podcast is not certified for credit. To participate in the full accredited activity and earn CME credit, use the link below.
In this podcast, experts Jonathan Goldman, MD; Sanja Dacic, MD, PhD; Deborah Doroshow, MD, PhD; and Anne S. Tsao, MD, MBA, discuss diagnostic and treatment strategies for patients with MET-altered non–small cell lung cancer.
Earn CME credit by completing the full accredited activity (available through September 19, 2026): https://www.gotoper.com/cours...
Pancreatic Cancer Treatment Advances Call for a Renewed Focus on the Role of Liposomal Irinotecan: With Jennifer B. Valerin, MD, PhD
In today’s episode, we spoke with Jennifer B. Valerin, MD, PhD. Dr Valerin is an assistant professor in the Divisions of Hematology and Oncology and Medicine at the University of California, Irvine School of Medicine.
In our exclusive interview, Dr Valerin discussed the clinical role of liposomal irinotecan (Onivyde) in pancreatic cancer management, factors influencing the decision to use liposomal irinotecan in practice, and developments she is excited to see as the pancreatic cancer landscape is shifting toward highly targeted and combination approaches.
Key Considerations for Health Equity and Patient-Centered Care in TNBC
Highlights from the PER® CME activity "Key Considerations for Health Equity and Patient-Centered Care in TNBC" — this podcast is not certified for credit. To participate in the full accredited activity and earn CME credit, use the link below.
In this podcast, experts Aditya Bardia, MD, MPH, FASCO, and Kathryn E. Post, PhD, ANP-BC, discuss key drivers of disparities in outcomes for triple-negative breast cancer and strategies for patient-centered communication, from shared decision-making to managing treatment-related toxicity.
Earn CME credit by completing the full accredited activity (available through July 31, 2027): https://www.gotoper.com/courses/key-considerations-for-health-equity-and-patient-centered-care-in-tnbc
Thi...
FDA Approval Insights: Gedatolisib Plus Fulvestrant ± Palbociclib for HR+, HER2-Negative, PIK3CA Wild-Type Advanced Breast Cancer: With Adam M. Brufsky, MD, PhD
In today’s episode, we spoke with Adam M. Brufsky, MD, PhD, about the FDA approval of gedatolisib (Revtorpyk) plus fulvestrant (Faslodex), with or without palbociclib (Ibrance), for the treatment of adult patients with hormone receptor–positive, HER2-negative advanced breast cancer without a PIK3CA mutation following progression on or after treatment with 1 or more lines of endocrine therapy in the metastatic setting. Dr Brufsky is a professor of medicine and the associate division chief for the Division of Hematology/Oncology in the Department of Medicine at the University of Pittsburgh School of Medicine; as well as medical dire...
Greater Flexibility and Improved QOL Represent Key Potential Benefits With Liquid TKI Formulations: With Jonathan Trent, MD, PhD
In today’s episode, we spoke with Jonathan Trent, MD, PhD, a professor in the Department of Medicine in the Division of Medical Oncology, associate director of Clinical Research, and the director of the Sarcoma Medical Research Program at the University of Miami Miller School of Medicine in Florida.
In our exclusive interview, Dr Trent discussed currently approved TKIs for patients with gastrointestinal stromal tumor (GIST), including imatinib (Gleevec), sunitinib (Sutent), regorafenib (Stivarga), and ripretinib (Qinlock). Trent dove into how these TKIs have improved outcomes for patients and touched on common adverse effects seen with these therapies, as...
Precision Oncology, Bispecific Antibodies, and Next-Generation Targeted Therapies Are Reshaping NSCLC Care: With Chandler Park, MD; Stephen V. Liu, MD
In this episode of Oncology Unplugged, host Chandler Park, MD, a medical oncologist at Norton Cancer Institute in Louisville, Kentucky, was joined by Stephen V. Liu, MD, the division chief of Hematology Oncology at MedStar Georgetown University Hospital, part of the MedStar Georgetown Cancer Institute, in Washington, DC.
Their discussion centered on the continued evolution of precision medicine in non–small cell lung cancer (NSCLC), highlighting advances in molecular testing, targeted therapies, immunotherapy, and emerging treatment strategies presented at the 2026 ASCO Annual Meeting. Drs Park and Liu explored how lung cancer has become a model for precision on...
From Trials to the Clinic: Incorporating New Advances in Metastatic TNBC
Highlights from the PER® CME activity "From Trials to the Clinic ‒ Incorporating New Advances in Metastatic TNBC" — this podcast is not certified for credit. To participate in the full accredited activity and earn CME credit, use the link below.
In this podcast, experts William Gradishar, MD, FASCO, FACP; and Kamel Abou Hussein, MD; discuss optimizing first-line treatment selection in metastatic triple-negative breast cancer (TNBC) with emerging antibody-drug conjugates (ADCs) and biomarker-guided strategies.
Earn CME credit by completing the full accredited activity (available through July 31, 2027): https://www.gotoper.com/courses/from-trials-to-the-clinic-incorporating-new-advances-in-metastatic-tnbc
This podcast, including the narra...
FDA Approval Insights: Subcutaneous Isatuximab Via an On-Body Delivery System Represents a “Game-Changer” in Multiple Myeloma: With Douglas W. Sborov, MD, MS
In today’s episode, we welcomed Douglas W. Sborov, MD, MS, to discuss the significance of the July 2026 FDA approval of isatuximab-irfc (Sarclisa Escena) for subcutaneous injection for multiple myeloma indications. Dr Sborov is a tenured professor of medicine in the Department of Internal Medicine in the Division of Hematology and Hematologic Malignancies and an adjunct associate professor in the Departments of Molecular Pharmaceutics and Biomedical Engineering at the University of Utah Huntsman Cancer Institute (HCI) in Salt Lake City, as well as director of the HCI Hematology Disease Center and Plasma Cell Dyscrasias (PCD) Program, co-leader of the He...
Positioning PD-L1/VEGF Bispecifics in First-Line Non–Small Cell Lung Cancer: With Solange Peters, MD, PhD
In today's episode, we spoke with Solange Peters, MD, PhD. Dr Peters is a full professor, and chair of medical oncology and the thoracic malignancies programme in the Department of Oncology at the University Hospital of Lausanne in Switzerland.
In our exclusive interview, Dr Peters discussed the rationale for pairing antiangiogenic activity with checkpoint inhibition upfront in non–small cell lung cancer (NSCLC), rather than sequencing them. She noted that prior attempts to combine or sequence bevacizumab (Avastin) with checkpoint inhibitors yielded only modest signals, hampered by bevacizumab’s long half-life and class-specific toxicities including bleeding risk that...
Biomarker-Driven Shifts Signal the Next Generation of mCRC Therapies: With Tanios S. Bekaii-Saab, MD
In today’s episode, we spoke with Tanios S. Bekaii-Saab, MD. Dr Bekaii-Saab is the David F. and Margaret T. Grohne Professor of Novel Therapeutics for Cancer Research I, at the Mayo Clinic College of Medicine and Science, the division chair of Hematology/Medical Oncology at Mayo Clinic, and co-leader of the Advanced Clinical and Translational Science Program and the disease group leader for Gastrointestinal Cancers for the Mayo Clinic Comprehensive Cancer Center in Phoenix, Arizona.
In our exclusive interview, Dr Bekaii-Saab discussed findings from the final analysis of cohort 3 of the phase 3 BREAKWATER trial (NCT04607421), which we...
Navigating Fixed-Durations Regimens in CLL and Improving Outcomes for High-Risk Patients: With John N. Allan, MD
In today’s episode, we spoke with John N. Allan, MD. Dr Allan is an associate attending physician at New York-Presbyterian Hospital and an associate professor of clinical medicine at Weill Cornell Medical College in New York, New York.
In our exclusive interview, Dr Allan discussed his review of the currently approved fixed-duration regimens for chronic lymphocytic leukemia (CLL). Regimens like venetoclax (Venclexta) plus obinutuzumab (Gazyva), ibrutinib (Imbruvica) plus venetoclax, acalabrutinib (Calquence) plus venetoclax, and venetoclax plus rituximab (Rituxan) were all regimens that Allan comparatively delved into. Additionally, Allan discussed insight provided by the review that clinical tri...
Sequencing Systemic and Liver-Directed Therapy in HLA-A*02:01–Negative Metastatic Uveal Melanoma: With Marlana M. Orloff, MD
In today’s episode, we spoke with Marlana M. Orloff, MD. Dr Orloff is the Alexander & Johnston Family Endowed Clinical Director in Uveal Melanoma, and associate professor at Thomas Jefferson University Hospital in Philadelphia, Pennsylvania.
In our exclusive interview, Dr Orloff discussed the distinct biology of uveal melanoma and why it has historically resisted systemic treatment. Unlike cutaneous melanoma, which carries a high tumor mutational burden and responds robustly to immune checkpoint inhibitors, uveal melanoma sits at the opposite end of the spectrum with low mutational burden, a predominantly liver-metastatic pattern, and an immune-tolerant microenvironment that renders tra...
Experts Bridge Oncology and Neurology to Catch LEMS Earlier in SCLC: With Misty D. Shields, MD, PhD; Triparna Sen, MD, PhD, MS; and Ditte Primdahl, MD
In today’s episode, we highlighted an OncLive Peer Exchange discussion about cancer-associated Lambert-Eaton myasthenic syndrome (LEMS) moderated by Misty D. Shields, MD, PhD. Dr Shields is an assistant professor of clinical medicine in the Department of Medicine in the Division of Hematology/Oncology at the Indiana University (IU) School of Medicine, as well as an adjunct assistant professor of medical & molecular genetics and an associate member of Experimental and Developmental Therapeutics at the IU Melvin and Bren Simon Comprehensive Cancer Center in Indianapolis. She was joined by Triparna Sen, MD, PhD, MS, a professor at The Ohio State Un...
FDA Approval Insights: Orca-T Raises the Bar for Allogeneic Transplants in Hematologic Malignancies: With Everett Meyer, MD, PhD
In today’s episode, we welcomed Everett Meyer, MD, PhD, an associate professor of medicine (blood & marrow transplantation), an associate professor of pediatrics (stem cell transplantation), and an associate professor of surgery (abdominal transplantation) at Stanford Medicine in California.
In the exclusive interview, Dr Meyer discussed the significance of the June 2026 FDA approval of allogeneic regulatory T cell–based immunotherapy with hematopoietic stem and progenitor cell (HSPC) and T cells-vldq (Tregzi; Orca-T) for use in matched donor hematopoietic stem cell transplantation (HSCT) with a myeloablative preparative regimen, for hematopoietic and immunologic reconstitution, and to improve chronic graft-vs-host dise...
ASCO 2026 ADC Data Clarify Some Strategies and Raise Further Questions for Breast Cancer Care: With Paolo Tarantino, MD, PhD
In today’s episode, we spoke with Paolo Tarantino, MD, PhD. Dr Tarantino is a breast medical oncologist and advanced fellow at Dana-Farber Cancer Institute and Harvard Medical School in Boston, Massachusetts.
In our exclusive interview, Dr Tarantino discussed practice-informing data regarding antibody-drug conjugates in breast cancer that were presented at the 2026 ASCO Annual Meeting, including the use of fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) plus pertuzumab (Perjeta) for first-line treatment of HER2-positive breast cancer based on findings from the phase 3 DESTINY-Breast09 trial (NCT04784715); updated safety data from the phase 3 DESTINY-Breast05 trial (NCT04622319) that indicated that T-DXd–associated inte...
FDA Approval Insights: First-Line Sacituzumab Govitecan Plus Pembrolizumab for PD-L1+ TNBC: With Sara M. Tolaney, MD, MPH
In today’s episode, we spoke with Sara M. Tolaney, MD, MPH, about the FDA approval of sacituzumab govitecan plus pembrolizumab (Keytruda) or pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex) for the first-line treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) whose tumors express PD-L1 as determined by an FDA-authorized test. Dr Tolaney is chief of the Division of Breast Oncology and associate director of the Susan F. Smith Center for Women’s Cancers and a senior physician at Dana-Farber Cancer Institute, as well as an associate professor of medicine at Harvard Medical School in B...
FDA Approval Insights: Orally Disintegrating Nilotinib Tablets for CML: With Jorge E. Cortes, MD; and Elias Jabbour, MD
In today’s episode, we spoke with Jorge E. Cortes, MD, and Elias Jabbour, MD. Dr Cortes is the chief of Hematology in the Division of Hematology and Oncology and the associate director for Translation at the UAB O’Neal Cancer Center in Birmingham, Alabama. Dr Jabbour is a professor of leukemia in the Department of Leukemia in the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center in Houston.
In our exclusive interview, Dr Cortes and Dr Jabbour discussed the orally disintegrating tablet formulation of nilotinib (Cavhanza) and its recent June 2026 FDA appr...
Treat Early and Aggressively: Optimizing Small Cell Lung Cancer Management Across the Community Setting: With Joshua Sabari, MD
In today’s episode, we spoke with Joshua K. Sabari, MD. Dr Sabari is an assistant professor in the Department of Medicine at NYU Grossman School of Medicine, and director of High Reliability Organization Initiatives at NYU Langone Health’s Perlmutter Cancer Center New York.
In our exclusive interview, Dr Sabari discussed the complexities of managing small cell lung cancer (SCLC) across both academic and community settings, emphasizing that nothing about this disease is straightforward. He stressed the importance of rapid diagnosis and staging, ideally within 48 to 72 hours given how quickly patients can deteriorate, and noted that in hi...
Hot Seat: Which Agent, and When? Integrating Next-Generation Endocrine Strategies Into HR+/HER2– Breast Cancer Management
Highlights from the PER® CME activity "Hot Seat: Which Agent, and When? Integrating Next-Generation Endocrine Strategies Into HR+/HER2– Breast Cancer Management" — this podcast is not certified for credit. To participate in the full accredited activity and earn CME credit, use the link below.
In this podcast, experts Ruta D. Rao, MD; Kamel Abou Hussein, MD; Jame Abraham, MD, FACP; and Paolo Tarantino, MD, PhD, discuss the data supporting the approvals of next-generation endocrine therapies for ESR1-mutated hormone receptor (HR)–positive, HER2-negative metastatic breast cancer, and how they think through these data when individualizing treatment recomme...
Cases and Conversations: Adopting New Treatment Strategies in Polycythemia Vera and Essential Thrombocythemia
Highlights from the PER® CME activity "Cases and Conversations: Adopting New Treatment Strategies in Polycythemia Vera and Essential Thrombocythemia" — this podcast is not certified for credit. To participate in the full accredited activity and earn CME credit, use the link below.
In this podcast, experts Gabriela Hobbs, MD; Rami Komrokji, MD; and Douglas A. Tremblay, MD; discuss the management of low-risk polycythemia vera (PV) based on the latest data.
Earn CME credit by completing the full accredited activity (available through June 30, 2027): https://www.gotoper.com/courses/cases-and-conversations-adopting-new-treatment-strategies-in-polycythemia-vera-and-essential-thrombocythemia-fvrl
This podcast, including the narration, was developed by...
ADCs and Bispecific Antibodies Across Solid Tumors: Integrating New Targets, New Data, and New Decisions
Highlights from the PER® CME activity "ADCs and Bispecific Antibodies Across Solid Tumors: Integrating New Targets, New Data, and New Decisions" — this podcast is not certified for credit. To participate in the full accredited activity and earn CME credit, use the link below.
In this podcast, experts William J. Gradishar, MD, FASCO, FACP; Rebecca Arend, MD, MSPH; Aaron Lisberg, MD; and Ulka Vaishampayan, MD, FASCO; discuss emerging antibody-drug conjugates and bispecific agents in lung, breast, endometrial, and prostate cancers, and how these agents may shift the therapeutic landscape in these disease.
Earn CME credit by com...
DLBCL 2026 UPDATE
Two Onc Docs, hosted by Samantha A. Armstrong, MD, and Karine Tawagi, MD, is a podcast dedicated to providing current and future oncologists and hematologists with the knowledge they need to ace their boards and deliver quality patient care. Dr Armstrong is a hematologist/oncologist and assistant professor of clinical medicine at Indiana University Health in Indianapolis. Dr Tawagi is a hematologist/oncologist and assistant professor of clinical medicine at the University of Illinois in Chicago.
In this episode, OncLive On Air® partnered with Two Onc Docs to deliver a comprehensive, board-focused review of diffuse large B-cell l...
Tumor Board: Evolving Immunotherapy Strategies for Stage I-III NSCLC
Highlights from the PER® CME activity "Tumor Board: Evolving Immunotherapy Strategies for Stage I-III NSCLC" — this podcast is not certified for credit. To participate in the full accredited activity and earn CME credit, use the link below.
In this podcast, experts Tina Cascone, MD, PhD; Puneeth Iyengar, MD, PhD; and Paula A. Ugalde Figueroa, MD; discuss evolving immunotherapy strategies for stage I to III non–small cell lung cancer (NSCLC), spanning surgical work-up and the shifting definition of resectability, perioperative immunotherapy trial data, the way that pathologic response guides treatment decisions, and the integration of radiation with immun...
Navigating Systemic Therapy Selection and Sequencing in Advanced CSCC: With Neil D. Gross, MD, FACS
In today’s episode, we spoke with Neil D. Gross, MD, FACS. Dr Gross is the medical director of Perioperative Surgical Services, section chief of Oropharynx Cancer, Surgery, and professor of head and neck surgery at The University of Texas MD Anderson Cancer Center in Houston.
In our exclusive interview, Dr Gross discussed the key biological and clinical distinctions between cutaneous squamous cell carcinoma (CSCC) and basal cell carcinoma (BCC), noting that although BCC is more indolent and less responsive to systemic therapies, including immunotherapy, CSCC carries a meaningful risk of nodal and distant metastases and has dem...
Cases and Conversations: Applying the Evidence – Real-World Strategies to Optimize Care for Patients With Myelofibrosis
Highlights from the PER® CME activity "Cases and Conversations: Applying the Evidence – Real-World Strategies to Optimize Care for Patients With Myelofibrosis" — this podcast is not certified for credit. To participate in the full accredited activity and earn CME credit, use the link below.
In this podcast, experts Ruben Mesa, MD, FACP; Andrew Kuykendall, MD; and Sangeetha Venugopal, MD, MS; discuss evolving management strategies for patients with MF, and considerations for selecting therapy based on patient-related and disease-related factors.
Earn CME credit by completing the full accredited activity (available through June 29, 2027): https://www.gotoper.com/courses/cases...
Tumor Board: Optimizing NSCLC Care—Leveraging the Latest Evidence on Targeted Therapy and Immuno-Oncology
Highlights from the PER® CME activity "Tumor Board: Optimizing NSCLC Care—Leveraging the Latest Evidence on Targeted Therapy and Immuno-Oncology" — this podcast is not certified for credit. To participate in the full accredited activity and earn CME credit, use the link below.
In this podcast, experts Justin Gainor, MD; Julia Rotow, MD; and Urs Weber, MD; discuss targeted therapies and immunotherapy to treat advanced non-small cell lung cancer (NSCLC).
Earn CME credit by completing the full accredited activity (available through June 29, 2027): https://www.gotoper.com/courses/tumor-board-optimizing-nsclc-careleveraging-the-latest-evidence-on-targeted-therapy-and-immuno-oncology-1fgr
This podcast, including the narration, was devel...
Oncology Town Hall: Updates From Chicago: Oral SERDs in HR+/HER2– Metastatic Breast Cancer—What the Latest Data Really Tell Us
Highlights from the PER® CME activity "Oncology Town Hall: Updates From Chicago: Oral SERDs in HR+/HER2− Metastatic Breast Cancer–What the Latest Data Really Tell Us" — this podcast is not certified for credit. To participate in the full accredited activity and earn CME credit, use the link below.
In this podcast, experts Virginia Kaklamani, MD, DSc; Kamel Abou Hussein, MD; Javier Cortés, MD, PhD; and Seth A. Wander, MD, PhD, discuss American Society of Clinical Oncology (ASCO) 2026 updates about data for oral selective estrogen receptor degraders (SERDs) to treat metastatic, HR-positive breast cancer.
Earn CME...
Cases and Conversations™: Optimizing Oral SERD-Based Therapy After CDK4/6 Inhibition in HR+/HER2– MBC
Highlights from the PER® CME activity "Cases and Conversations: Optimizing Oral SERD-Based Therapy After CDK4/6 Inhibition in HR+/HER2– MBC" — this podcast is not certified for credit. To participate in the full accredited activity and earn CME credit, use the link below.
In this podcast, experts Virginia Kaklamani, MD, DSc; Antonio Giordano, MD, PhD; Nadia Harbeck, MD, PhD; and Sarah Sammons, MD, discuss the use of oral SERD-based therapy in the treatment of HR+/HER2– metastatic breast cancer through a series of clinical cases.
Earn CME credit by completing the full accredited activity (available through June 30...
RECITE Findings Highlight the Potential of Romiplostim to Preserve Chemotherapy Delivery in GI Cancer: With Gerald Soff, MD
Welcome to OncLive On Air®! I’m your host today, Courtney Flaherty.
OncLive On Air is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.
In this episode of OncLive On Air, Gerald Soff, MD, sat down with OncLive to discuss findings from the phase 3 RECITE trial (NCT03362177), which evaluated romiplostim for the management of chemotherapy-induced thrombocytopenia (CIT) in patients with...
